BPG致力于知识的发现和传播
在F6Publishing中引用其的文章
For: Wu CQ, Zhou X, Li CP, He QL, Chen ZH, Ding SB, Deng L, Chen LL, Jiang K, Dong CK, Hu L, Zhu GB, Zhang CG, Zhang Y, Wu LL, Li W, Mao YH, Zhang H, Ai X, He YQ, Ma Y, He SY. Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for Helicobacter pylori eradication in Sichuan Province, China. World J Gastroenterol 2025; 31(47): 114377 [PMID: 41479756 DOI: 10.3748/wjg.v31.i47.114377]
URL: https://www.wjgnet.com/1009-3079/full/v31/i47/114377.htm
编号 Citing Articles
1
Aitor Lanas-Gimeno, Angel Lanas. Recent developments in the therapeutic management of acid-related gastrointestinal diseasesExpert Review of Gastroenterology & Hepatology 2026;  doi: 10.1080/17474124.2026.2706854
2
Tian-Qi Liu, Kang-Ning Li, Qing Chen. From clinical efficacy to population health: Implementing vonoprazan-amoxicillin dual therapy for <i>Helicobacter pylori</i> controlWorld Journal of Gastroenterology 2026; 32(12): 116953 doi: 10.3748/wjg.v32.i12.116953
3
Ling He, Jing Hong, Meng-Lin Chen, Hou-Shu Tu. Vonoprazan-amoxicillin dual therapy for <i>Helicobacter pylori</i> eradication: Clinical, pharmacogenetic, and microbiome perspectivesWorld Journal of Gastroenterology 2026; 32(26): 116530 doi: 10.3748/wjg.116530
4
Hideki Mori, Hidekazu Suzuki. Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppressionJournal of Gastroenterology 2026;  doi: 10.1007/s00535-026-02422-4